行情

LJPC

LJPC

Jolla制药
NASDAQ

实时行情|Nasdaq Last Sale

6.36
+0.70
+12.37%
交易中 15:05 04/08 EDT
开盘
5.75
昨收
5.66
最高
6.39
最低
5.65
成交量
47.51万
成交额
--
52周最高
13.90
52周最低
2.300
市值
1.73亿
市盈率(TTM)
-1.4798
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测LJPC价格均价为13.75,最高价位20.00,最低价为4.000。

EPS

LJPC 新闻

更多
  • 美联储会议纪要:经济前景面临“极大程度”不确定性
  • 新浪美股 · 54分钟前
  • 经济复苏为时尚早 全球市场持续震荡 欧股收盘走低
  • 新浪财经综合 · 1小时前
  • 调查:四分之一的美国人因疫情封锁措施失业或减薪
  • 新浪美股 · 1小时前
  • 美国调查丨快递小哥不干了!
  • 央视 · 2小时前

所属板块

生物技术和医学研究
+3.09%
制药与医学研究
+3.06%

热门股票

代码
价格
涨跌幅

LJPC 简况

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
展开

微牛提供La Jolla Pharmaceutical Company(NASDAQ-LJPC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的LJPC股票新闻,以帮助您做出投资决策。